Concepedia

Mary Rose Keller

MR

3

Publications

55

Citations

3

H-Index

2018

Active since

Affiliations

Heron Therapeutics (United States)(Current)

GTx (United States)

Mary Rose Keller is an author at Heron Therapeutics (United States).

Publications per year

2018–2018

3

Publications

3

Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation

Thomas Ottoboni, Mary Rose Keller, Matt Cravets et al. · Drug Design Development and Therapy · 2018 · 23 citations · Full text

Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects

Tom Ottoboni, Michael Lauw, Mary Rose Keller et al. · Future Oncology · 2018 · 21 citations · Full text

HTX-019 via 2-Min Injection or 30-Min Infusion in Healthy Subjects

Thomas Ottoboni, Michael Lauw, Mary Rose Keller et al. · Future Oncology · 2018 · 11 citations · Full text

Rows per page

1–3 of 3